155148-31-5 | Plerixafor octahydrochloride

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$7.00	$5.00
5mg	95%	in stock	$10.00	$7.00
10mg	95%	in stock	$15.00	$10.00
50mg	95%	in stock	$33.00	$23.00
100mg	95%	in stock	$49.00	$34.00
250mg	95%	in stock	$90.00	$63.00
1g	95%	in stock	$236.00	$165.00
5g	95%	in stock	$824.00	$577.00

Description

• Catalog Number: AA77110
• Chemical Name: Plerixafor octahydrochloride
• CAS Number: 155148-31-5
• Molecular Formula: C28H62Cl8N8
• Molecular Weight: 794.4695
• MDL Number: MFCD00927130
• SMILES: C1CNCCN(CCCNCCNC1)Cc1ccc(cc1)CN1CCNCCCNCCNCCC1.Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl

Computed Properties

• Complexity: 456
• Covalently-Bonded Unit Count: 9
• Heavy Atom Count: 44
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 14
• Rotatable Bond Count: 4

Upstream Synthesis Route

This product, $name$, plays a crucial role in chemical synthesis as a versatile ligand in coordination chemistry. Specifically, it serves as a chelating agent, forming stable complexes with various metal ions due to its unique chemical structure. The 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] hydrochloride (1:8) ligand is known for its ability to coordinate with metal ions in a specific manner, influencing the reactivity and selectivity of chemical reactions. In chemical synthesis, this compound is commonly utilized to control reaction pathways, enhance catalytic activities, and facilitate the formation of desired products. Its application in coordination chemistry offers researchers a powerful tool for designing and manipulating molecular structures with precision and efficiency.

Literature

• Naringin enhances endothelial progenitor cell (EPC) proliferation and tube formation capacity through the CXCL12/CXCR4/PI3K/Akt signaling pathway.

  Chemico-biological interactions 20180425

• Inhibitory effects of 3,3'-diindolylmethane on epithelial-mesenchymal transition induced by endocrine disrupting chemicals in cellular and xenograft mouse models of breast cancer.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20171101

• A Novel CXCR4 Antagonist CX549 Induces Neuroprotection in Stroke Brain.

  Cell transplantation 20170401

• Resveratrol suppresses vascular endothelial growth factor secretion via inhibition of CXC-chemokine receptor 4 expression in ARPE-19 cells.

  Molecular medicine reports 20150701

• Expression and regulation of stromal cell-derived factor-1 (SDF1) and chemokine CXC motif receptor 4 (CXCR4) in equine and bovine preovulatory follicles.

  Molecular and cellular endocrinology 20140625

• Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity.

  Toxicology 20131215

• Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma.

  Journal of clinical apheresis 20121101

• Long-term administration of AMD3100, an antagonist of SDF-1/CXCR4 signaling, alters fracture repair.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20121101

• Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors.

  Bone marrow transplantation 20121001

• Inhibition of stromal CXCR4 impairs development of lung metastases.

  Cancer immunology, immunotherapy : CII 20121001

• Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20121001

• Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.

  Blood 20120927

• Noncyclam tetraamines inhibit CXC chemokine receptor type 4 and target glioma-initiating cells.

  Journal of medicinal chemistry 20120913

• Plerixafor, a CXCR4 antagonist, mitigates skin radiation-induced injury in mice.

  Radiation research 20120901

• Vinorelbine inhibits angiogenesis and 95D migration via reducing hypoxic fibroblast stromal cell-derived factor 1 secretion.

  Experimental biology and medicine (Maywood, N.J.) 20120901

• Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.

  Bone marrow transplantation 20120801

• European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.

  Bone marrow transplantation 20120801

• Plerixafor in AL amyloidosis: improved graft composition and faster lymphocyte recovery after auto-SCT in patient with end-stage renal-disease.

  Bone marrow transplantation 20120801

• Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120801

• Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.

  Transfusion 20120801

• Progenitor cell mobilizing treatments prevent experimental transplant arteriosclerosis.

  The Journal of surgical research 20120801

• Who should be really considered as a poor mobilizer in the plerixafor era?

  Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 20120801

• Blood graft composition after plerixafor injection in patients with NHL.

  European journal of haematology 20120801

• Plerixafor use in patients with previous mobilization failure: A multicenter experience.

  Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 20120801

• CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.

  Neoplasia (New York, N.Y.) 20120801

• New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.

  Journal of medicinal chemistry 20120726

• Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF.

  Bone marrow transplantation 20120701

• High white blood cell concentration in the peripheral blood stem cell product can induce seizures during infusion of autologous peripheral blood stem cells.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120701

• Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use.

  Annals of hematology 20120701

• Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: clinical and economic outcomes.

  American journal of hematology 20120701

• Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.

  Pharmacotherapy 20120701

• CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling.

  British journal of cancer 20120626

• Pharmacophore-based small molecule CXCR4 ligands.

  Bioorganic & medicinal chemistry letters 20120615

• Exposure to ambient air fine particulate matter prevents VEGF-induced mobilization of endothelial progenitor cells from the bone marrow.

  Environmental health perspectives 20120601

• Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.

  Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 20120601

• Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.

  Leukemia 20120501

• α-Tocopherol succinate- and AMD3100-mobilized progenitors mitigate radiation-induced gastrointestinal injury in mice.

  Experimental hematology 20120501

• Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists.

  European journal of medicinal chemistry 20120501

• A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.

  Blood 20120426

• A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor.

  Bone marrow transplantation 20120401

• Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.

  Transfusion 20120401

• AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.

  Haematologica 20120401

• Heparan sulfate mimetics can efficiently mobilize long-term hematopoietic stem cells.

  Haematologica 20120401

• The use of plerixafor in hematopoietic progenitor cell collection in pediatric patients: a single center experience.

  Cytotherapy 20120401

• Expression of chemokine CXCL12 and its receptor CXCR4 in folliculostellate (FS) cells of the rat anterior pituitary gland: the CXCL12/CXCR4 axis induces interconnection of FS cells.

  Endocrinology 20120401

• [Anti-angiogenesis effect of AMD3100 in oxygen-induced retinopathy mice].

  [Zhonghua yan ke za zhi] Chinese journal of ophthalmology 20120401

• S1P promotes murine progenitor cell egress and mobilization via S1P1-mediated ROS signaling and SDF-1 release.

  Blood 20120315

• Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma.

  Pediatric blood & cancer 20120301

• Priming of hematopoietic progenitor cells by plerixafor and filgrastim in children with previous failure of mobilization with chemotherapy and/or cytokine treatment.

  Journal of pediatric hematology/oncology 20120301

• Discovery of novel stem cell mobilizers that target the CXCR4 receptor.

  ChemMedChem 20120206

• Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120201

• Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.

  European journal of haematology 20120201

• Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120201

• Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice.

  Blood 20120119

• PBSCs Sphingoling along S1P/S1P1 axis.

  Blood 20120119

• Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.

  Bone marrow transplantation 20120101

• Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization.

  Transfusion 20120101

• Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists.

  Leukemia & lymphoma 20120101

• Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects.

  Molecular therapy : the journal of the American Society of Gene Therapy 20120101

• In vivo imaging of ligand receptor binding with Gaussia luciferase complementation.

  Nature medicine 20120101

• Optimizing stem cell collection through CXCR4 antagonists.

  Frontiers in bioscience (Scholar edition) 20120101

• The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.

  Journal of clinical apheresis 20120101

• CXCR4 expression in prostate cancer progenitor cells.

  PloS one 20120101

• Economic evaluation of plerixafor for stem cell mobilization.

  The American journal of managed care 20120101

• Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment.

  Journal of hematology & oncology 20120101

• Efficacy and adverse effects of the antiviral compound plerixafor in feline immunodeficiency virus-infected cats.

  Journal of veterinary internal medicine 20120101

• Initial assessment of the role of CXC chemokine receptor 4 after polytrauma.

  Molecular medicine (Cambridge, Mass.) 20120101

• Hematopoietic stem cell mobilization: a clinical protocol.

  Methods in molecular biology (Clifton, N.J.) 20120101

• [Hematopoietic stem cells mobilization: state of the art in 2011 and perspectives].

  Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 20111201

• Evaluation of a fluorescent derivative of AMD3100 and its interaction with the CXCR4 chemokine receptor.

  Chembiochem : a European journal of chemical biology 20111125

• The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.

  Blood 20111103

• The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.

  Blood 20111103

• AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome.

  Journal of cellular and molecular medicine 20111001

• Effectiveness and cost analysis of 'just-in-time' salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.

  Transfusion 20111001

• The effect of gp120 on morphine's antinociceptive and neurophysiological actions.

  Brain, behavior, and immunity 20111001

• Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late.

  Leukemia & lymphoma 20110901

• Novel strategies for blood stem cell mobilization: special focus on plerixafor.

  Expert opinion on biological therapy 20110901

• Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.

  Drugs 20110820

• Astrocytes and pericytes cooperatively maintain a capillary-like structure composed of endothelial cells on gel matrix.

  Brain research 20110811

• Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

  Bone marrow transplantation 20110801

• Successful mobilization with plerixafor and autologous hematopoietic SCT in a patient with refractory Hodgkin's lymphoma and Gaucher disease.

  Bone marrow transplantation 20110801

• Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.

  Bone marrow transplantation 20110801

• Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110801

• Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist.

  Leukemia 20110801

• Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells.

  Leukemia 20110801

• [New molecular targets and new clinical practices for hematopoietic stem cell mobilization].

  Bulletin du cancer 20110801

• [Development of novel agents for multiple myeloma; now and the future].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20110801

• Plerixafor 'just in time' for stem cell mobilization in a normal donor.

  Bone marrow transplantation 20110701

• Acrolein inhalation prevents vascular endothelial growth factor-induced mobilization of Flk-1+/Sca-1+ cells in mice.

  Arteriosclerosis, thrombosis, and vascular biology 20110701

• Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor.

  Experimental hematology 20110701

• In and out of the niche: perspectives in mobilization of hematopoietic stem cells.

  Experimental hematology 20110701

• Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.

  American journal of hematology 20110701

• Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.

  Leukemia research 20110601

• Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells.

  European journal of haematology 20110601

• Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.

  Current molecular medicine 20110601

• Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution.

  Clinical lymphoma, myeloma & leukemia 20110601

• [Some research progress of CXCR4 antagonist AMD3100].

  Zhongguo shi yan xue ye xue za zhi 20110601

• Successful mobilization of PBSCs in a healthy volunteer donor by addition of plerixafor after failure of mobilization with G-CSF alone.

  Bone marrow transplantation 20110501

• Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110501

• Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.

  Transfusion 20110501

• Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.

  Annals of hematology 20110501

• Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.

  Bone marrow transplantation 20110501

• Tanshinone IIA increases recruitment of bone marrow mesenchymal stem cells to infarct region via up-regulating stromal cell-derived factor-1/CXC chemokine receptor 4 axis in a myocardial ischemia model.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20110415

• CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

• Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.

  Bone marrow transplantation 20110401

• Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor.

  Cytotherapy 20110401

• Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.

  European journal of haematology 20110401

• A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers.

  British journal of haematology 20110401

• Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.

  Expert review of anticancer therapy 20110401

• Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.

  Bone marrow transplantation 20110301

• The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.

  Bone marrow transplantation 20110301

• CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth.

  Experimental hematology 20110301

• The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.

  The Journal of pathology 20110301

• Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients.

  Bone marrow transplantation 20110201

• Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases.

  European journal of cancer (Oxford, England : 1990) 20110201

• Importance of receptor flexibility in binding of cyclam compounds to the chemokine receptor CXCR4.

  Journal of chemical information and modeling 20110124

• Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.

  Bone marrow transplantation 20110101

• Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.

  Bone marrow transplantation 20110101

• The feasibility of plerixafor as a second-line stem cell mobilizing agent in children.

  Journal of pediatric hematology/oncology 20110101

• Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1.

  Journal of immunology (Baltimore, Md. : 1950) 20110101

• The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation.

  Leukemia 20110101

• Effect of chemokine receptor CXCR4 on hypoxia-induced pulmonary hypertension and vascular remodeling in rats.

  Respiratory research 20110101

• Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.

  Acta clinica Belgica 20110101

• Stem cells in acute liver failure.

  Advances in surgery 20110101

• Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil) and granulocyte-colony stimulating factor.

  Drug design, development and therapy 20110101

• Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF-1/CXCR4 axis.

  PloS one 20110101

• CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis.

  PloS one 20110101

• Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity.

  Journal of medicinal chemistry 20101223

• CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche.

  Cancer research 20101215

• Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists.

  Blood 20101209

• The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.

  The Journal of biological chemistry 20101203

• Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies.

  European journal of haematology 20101201

• Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.

  Pharmacology & therapeutics 20101201

• Plerixafor dosing and administration in a patient with dialysis-dependent renal failure.

  The Annals of pharmacotherapy 20101201

• Can every patient be mobilized?

  Best practice & research. Clinical haematology 20101201

• CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.

  British journal of cancer 20101101

• Chronic AMD3100 antagonism of SDF-1alpha-CXCR4 exacerbates cardiac dysfunction and remodeling after myocardial infarction.

  Journal of molecular and cellular cardiology 20101001

• Phosphodiesterase-5 inhibitor tadalafil acts on endothelial progenitor cells by CXCR4 signalling.

  Current drug delivery 20101001

• Stem cell mobilization is life saving in an animal model of acute liver failure.

  Annals of surgery 20101001

• Profound blockage of CXCR4 signaling at multiple points using the synergy between plerixafor, mirtazapine, and clotrimazole as a new glioblastoma treatment adjunct.

  Turkish neurosurgery 20101001

• Novel monocyclam derivatives as HIV entry inhibitors: Design, synthesis, anti-HIV evaluation, and their interaction with the CXCR4 co-receptor.

  ChemMedChem 20100802

• Plerixafor and pegylated filgrastim: a case of safe and effective hematopoietic stem cell mobilization.

  Bone marrow transplantation 20100801

• Decreased circulating progenitor cell number and failed mechanisms of stromal cell-derived factor-1alpha mediated bone marrow mobilization impair diabetic tissue repair.

  Diabetes 20100801

• Repeated phlebotomy augments angiogenesis to improve blood flow in murine ischemic legs.

  American journal of physiology. Heart and circulatory physiology 20100801

• Plerixafor. Only for certain patients when G-CSF stem cell mobilisation fails.

  Prescrire international 20100801

• Evaluation of CXCR4 inhibition in the prevention and intervention model of laser-induced choroidal neovascularization.

  Investigative ophthalmology & visual science 20100701

• Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells.

  Current opinion in hematology 20100701

• Plerixafor given before the third leukapheresis to rescue an unsuccessful stem cell mobilization with CY and G-CSF.

  Bone marrow transplantation 20100601

• Safe and effective use of plerixafor plus G-CSF in dialysis-dependent renal failure.

  American journal of hematology 20100601

• CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer.

  Anticancer research 20100601

• HIV-1 tropism.

  Protein & cell 20100601

• Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography.

  Cancer research 20100515

• Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20100501

• Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex.

  Leukemia 20100501

• Plerixafor: a peripheral blood stem cell mobilizer.

  Pharmacotherapy 20100501

• Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.

  Clinical therapeutics 20100501

• Plerixafor (Mozobil).

  The Medical letter on drugs and therapeutics 20100405

• Molecular Medicine - CHI's 17th International Tri-Conference: Mastering Medicinal Chemistry - CHI's Seventh Annual Conference.

  IDrugs : the investigational drugs journal 20100401

• Expression and function of CXCL12/CXCR4 in rat urinary bladder with cyclophosphamide-induced cystitis.

  American journal of physiology. Renal physiology 20100301

• Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.

  Bone marrow transplantation 20100201

• SDF-1alpha/CXCL12 enhances GABA and glutamate synaptic activity at serotonin neurons in the rat dorsal raphe nucleus.

  Neuropharmacology 20100201

• Oxovanadium(IV) cyclam and bicyclam complexes: potential CXCR4 receptor antagonists.

  Inorganic chemistry 20100201

• New Drugs2010, PART 1.

  Nursing 20100201

• Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.

  Bone marrow transplantation 20100101

• A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20100101

• Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.

  The Annals of pharmacotherapy 20100101

• Alpha-tocopherol succinate protects mice from gamma-radiation by induction of granulocyte-colony stimulating factor.

  International journal of radiation biology 20100101

• CXCR4 in clinical hematology.

  Current topics in microbiology and immunology 20100101

• Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4.

  BMC cancer 20100101

• FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.

  Oncology 20100101

• Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model.

  PloS one 20100101

• Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs.

  Journal of clinical apheresis 20100101

• Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.

  Molecular cancer 20100101

• Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer.

  Acta haematologica 20100101

• Successful stem-cell mobilization and transplantation using plerixafor in a patient with a germ cell tumor.

  Hematology/oncology and stem cell therapy 20100101

• Booster of plerixafor can be successfully used in addition to chemotherapy-based regimen to rescue stem cell mobilization failure.

  Annals of transplantation 20100101

• Glycosaminoglycans and syndecan-4 are involved in SDF-1/CXCL12-mediated invasion of human epitheloid carcinoma HeLa cells.

  Biochimica et biophysica acta 20091201

• Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20091201

• Mobilization of hematopoietic stem cells into the peripheral blood.

  Expert review of hematology 20091201

• [Stem cell harvesting after plerixafor treatment].

  Ugeskrift for laeger 20091116

• [Mobilisation of haematopoietic stem cells with plerixafor--secondary publication].

  Ugeskrift for laeger 20091102

• International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

  Leukemia 20091001

• Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.

  Leukemia & lymphoma 20091001

• Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091001

• Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia.

  Leukemia & lymphoma 20091001

• Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.

  Blood 20090917

• Extracellular calcium increases CXCR4 expression on bone marrow-derived cells and enhances pro-angiogenesis therapy.

  Journal of cellular and molecular medicine 20090901

• Advances in mobilization for the optimization of autologous stem cell transplantation.

  Leukemia & lymphoma 20090901

• Apolipoproteins D and E3 exert neurotrophic and synaptogenic effects in dorsal root ganglion cell cultures.

  Neuroscience 20090818

• BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells.

  Blood 20090813

• Bis-14-membered ring diketal diamines: synthesis and evaluation of their anti-HIV and anti-tumoral activities.

  European journal of medicinal chemistry 20090801

• Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells.

  Drugs of today (Barcelona, Spain : 1998) 20090701

• Modulation of cocaine-induced activity by intracerebral administration of CXCL12.

  Neuroscience 20090616

• Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

  Blood 20090611

• Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

  Blood 20090604

• Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience.

  Bone marrow transplantation 20090601

• Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090601

• New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses.

  Molecules (Basel, Switzerland) 20090522

• Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.

  Blood 20090507

• AMD3100 is a CXCR7 ligand with allosteric agonist properties.

  Molecular pharmacology 20090501

• CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukaemia cells to the bone marrow via activation of p38MAPK.

  British journal of haematology 20090501

• CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

  Blood 20090430

• Morphine increases brain levels of ferritin heavy chain leading to inhibition of CXCR4-mediated survival signaling in neurons.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20090225

• Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090201

• Plerixafor.

  Nature reviews. Drug discovery 20090201

• Plerixafor approved for autologous hematopoietic stem-cell transplantation.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090115

• Differential mobilization of subsets of progenitor cells from the bone marrow.

  Cell stem cell 20090109

• Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090101

• Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.

  Drugs 20090101

• Recent patents regarding the discovery of small molecule CXCR4 antagonists.

  Expert opinion on therapeutic patents 20090101

• CXCR4 and mobilization of hematopoietic precursors.

  Methods in enzymology 20090101

• A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study.

  Cytotherapy 20090101

• Targeted antagonism of CXCR4 mobilizes progenitor cells under investigation for cardiovascular disease.

  Cytotherapy 20090101

• Mechanism of primitive duct formation in the pancreas and submandibular glands: a role for SDF-1.

  BMC developmental biology 20090101

• Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors.

  Molecular pharmacology 20081201

• The discovery of antiviral agents: ten different compounds, ten different stories.

  Medicinal research reviews 20081101

• Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.

  Expert opinion on biological therapy 20081101

• A novel CXCR4 antagonist for hematopoietic stem cell mobilization.

  Expert opinion on investigational drugs 20081101

• A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20081101

• Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors.

  ChemMedChem 20081001

• Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080901

• Curcumin modulates SDF-1alpha/CXCR4-induced migration of human retinal endothelial cells (HRECs).

  Investigative ophthalmology & visual science 20080801

• SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia.

  Blood 20080701

• Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.

  Antimicrobial agents and chemotherapy 20080601

• NeoR6 inhibits HIV-1-CXCR4 interaction without affecting CXCL12 chemotaxis activity.

  Biochimica et biophysica acta 20080601

• Tonic activation of CXC chemokine receptor 4 in immature granule cells supports neurogenesis in the adult dentate gyrus.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20080423

• Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026.

  Molecular pharmacology 20080401

• Stromal cell-derived factor-1 promotes bone marrow-derived cells differentiation to cardiomyocyte phenotypes in vitro.

  Cell proliferation 20080401

• HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.

  AIDS (London, England) 20080102

• Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.

  Retrovirology 20080101

• Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis.

  Journal of translational medicine 20080101

• Elevated CXCL12 expression in the bone marrow of NOD mice is associated with altered T cell and stem cell trafficking and diabetes development.

  BMC immunology 20080101

• Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells.

  Leukemia research 20071101

• Mobilization of peripheral blood stem cells.

  Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 20071001

• Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.

  The Journal of biological chemistry 20070914

• Stromal cell-derived factor-1 induces matrix metalloprotease-13 expression in human chondrocytes.

  Molecular pharmacology 20070901

• Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1alpha/CXCR4 via PI3K/Akt/eNOS signal transduction pathway.

  Journal of cardiovascular pharmacology 20070901

• HIV entry inhibitors.

  Lancet (London, England) 20070707

• CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathy.

  Brain, behavior, and immunity 20070701

• Modification of post-myocardial infarction granulocyte-colony stimulating factor therapy with myelo-suppressives.

  Circulation journal : official journal of the Japanese Circulation Society 20070401

• Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion.

  World journal of gastroenterology 20070314

• Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791.

  Drugs in R&D 20070101

• Mobilization of bone marrow-derived progenitors.

  Handbook of experimental pharmacology 20070101

• Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates.

  Current medicinal chemistry 20070101

• CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061115

• Configurationally restricted bismacrocyclic CXCR4 receptor antagonists.

  Journal of medicinal chemistry 20061019

• Meninges control tangential migration of hem-derived Cajal-Retzius cells via CXCL12/CXCR4 signaling.

  Nature neuroscience 20061001

• HIV co-receptor inhibitors as novel class of anti-HIV drugs.

  Antiviral research 20060901

• Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.

  Biochemical pharmacology 20060828

• Axonal transport of human immunodeficiency virus type 1 envelope protein glycoprotein 120 is found in association with neuronal apoptosis.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20060621

• AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates.

  Blood 20060501

• Stromal cell-derived factor-1alpha modulation of the excitability of rat substantia nigra dopaminergic neurones: presynaptic mechanisms.

  Journal of neurochemistry 20060301

• The temperature arrested intermediate of virus-cell fusion is a functional step in HIV infection.

  Virology journal 20060101

• The development of an europium-GTP assay to quantitate chemokine antagonist interactions for CXCR4 and CCR5.

  Assay and drug development technologies 20051201

• A CXCR4-dependent chemorepellent signal contributes to the emigration of mature single-positive CD4 cells from the fetal thymus.

  Journal of immunology (Baltimore, Md. : 1950) 20051015

• Regulation of neuronal P53 activity by CXCR 4.

  Molecular and cellular neurosciences 20050901

• Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100.

  Mini reviews in medicinal chemistry 20050901

• Stromal cell-derived factor-1alpha directly modulates voltage-dependent currents of the action potential in mammalian neuronal cells.

  Journal of neurochemistry 20050501

• The chemokine stromal cell-derived factor-1 regulates the migration of sensory neuron progenitors.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050420

• Innovative strategies for PBPC mobilization.

  Cytotherapy 20050101

• Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis.

  Arthritis research & therapy 20050101

• Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins.

  Journal of virology 20041001

• Cyclam complexes and their applications in medicine.

  Chemical Society reviews 20040510

• Mechanism of feline immunodeficiency virus envelope glycoprotein-mediated fusion.

  Virology 20040410

• Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor.

  The Journal of biological chemistry 20040123

• New bicyclam-GalCer analogue conjugates: synthesis and in vitro anti-HIV activity.

  Bioorganic & medicinal chemistry letters 20040119

• The chemokine receptor CXCR4 and not the N-methyl-D-aspartate receptor mediates gp120 neurotoxicity in cerebellar granule cells.

  Journal of neuroscience research 20040101

• AMD3100 conjugates as components of targeted nonviral gene delivery systems: synthesis and in vitro transfection efficiency of CXCR4-expressing cells.

  Bioconjugate chemistry 20040101

• Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists.

  Retrovirology 20040101

• Resistance to HIV-1 entry inhibitors.

  Current drug targets. Infectious disorders 20031201

• Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists.

  The Journal of biological chemistry 20031121

• Direct synthesis of 1,1'-[1,4-phenylenebis(methylene)]-bis- 1,4,8,11-tetraazacyclotetradecane octahydrochloride (AMD 3100) without the use of protecting groups.

  The Journal of organic chemistry 20030808

• Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry.

  FEBS letters 20030710

• Brain-derived neurotrophic factor inhibits human immunodeficiency virus-1/gp120-mediated cerebellar granule cell death by preventing gp120 internalization.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20030702

• The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.

  Journal of virology 20030401

• Establishment of an in vitro assay system mimicking human immunodeficiency virus type 1-induced neural cell death and evaluation of inhibitors thereof.

  Journal of virological methods 20030301

• Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor.

  Biochemistry 20030128

• Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20030101

• Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.

  Cancer research 20021015

• Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.

  FEBS letters 20020911

• Structure and dynamics of metallomacrocycles: recognition of zinc xylyl-bicyclam by an HIV coreceptor.

  Journal of the American Chemical Society 20020807

• A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists.

  The Journal of biological chemistry 20020705

• Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents.

  Journal of enzyme inhibition and medicinal chemistry 20020401

• AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice.

  Journal of immunology (Baltimore, Md. : 1950) 20011015

• Hamao Umezawa Memorial Award Lecture: 'An Odyssey in the Viral Chemotherapy Field'.

  International journal of antimicrobial agents 20011001

• Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.

  The Journal of biological chemistry 20010914

• Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists.

  Immunology letters 20010801

• Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.

  Molecular pharmacology 20010701

• HIV fusion and its inhibition.

  Antiviral research 20010501

• Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor.

  The Journal of biological chemistry 20010427

• Increase of R5 HIV-1 infection and CCR5 expression in T cells treated with high concentrations of CXCR4 antagonists and SDF-1.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20010301

• Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100.

  Journal of acquired immune deficiency syndromes (1999) 20001001

• Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists.

  Molecular pharmacology 20000501

• Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection.

  AIDS research and human retroviruses 20000501

• The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis.

  Antimicrobial agents and chemotherapy 20000101

• Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.

  Journal of medicinal chemistry 19990923

• T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.

  Journal of virology 19990201

• New bicyclam-AZT conjugates: design, synthesis, anti-HIV evaluation, and their interaction with CXCR-4 coreceptor.

  Journal of medicinal chemistry 19990128

• A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.

  Biochemical and biophysical research communications 19981230

• AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

  Nature medicine 19980101

• Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.

  The Journal of experimental medicine 19971020

• Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.

  Antiviral research 19970801

• The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding.

  Antiviral research 19960301

• Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1.

  Antiviral research 19960301

• The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication.

  Journal of virology 19960201

• Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors.

  Journal of medicinal chemistry 19950915

• Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100.

  Antimicrobial agents and chemotherapy 19940401